explore -WSS

explore

author：Wikipedia 2025-09-06 02:04:13 - browse：7949

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Intercept Pharmaceuticals sells itself for less than $1 billion

explore

WSS

WHO recommends dropping component of many flu vaccines

Former Georgia lieutenant governor says he received grand jury subpoena

Shingles, which affected Dianne Feinstein, is on the rise

The painfully weak evidence on taking collagen to treat arthritis

CDC launches VaccineFinder tool to locate Covid

Lessons Learned: This is why you network to find that industry job you want

leisure time

explore

knowledge

How to save PrEP access — and even expand it

Judge rejects Trump's counterclaim against E. Jean Carroll

Sports medicine is finally prioritizing gender equality

Would Medicare drug price negotiations stall in a shutdown?

At least 13 dead in Texas as scorching temps continue

Did you have Obamacare on your GOP debate bingo card?

Jerome Adams on the need for new antivirals for Covid

WHO recommends dropping component of many flu vaccines

Continuity nursing helped my family in our darkest PICU moments

FDA seeks to regulate lab

focus

Medicaid, Medicare dual

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Germany receives 178 compensation applications from gay servicepeople over discrimination

Biogen shutters digital health group, ends Apple study, in cost cutting move

Shingles, which affected Dianne Feinstein, is on the rise

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

explore

focus

hotspot

leisure time